Archive for the ‘Cervical Cancer / HPV Vaccine’ Category
Thursday, May 15th, 2008
Health Discovery Corporation (OTCBB: HDVY), a leader in support vector machine (SVM) based molecular diagnostics development, and DCL Medical Laboratories LLC, Indianapolis, IN, a full-service clinical reference laboratory focused on women's health, today announced the signing of a Letter of Intent for the companies to jointly develop an SVM-based computer ...
Posted in Cervical Cancer / HPV Vaccine | No Comments »
Thursday, May 15th, 2008
New Zealand Prime Minister Helen Clark on Friday announced a new program that will provide about $128 million over five years to vaccinate girls ages 12 to 18 against cervical cancer, the New Zealand Herald reports. As of Sept. 1, all girls born in 1990 and 1991 can receive a ...
Posted in Cervical Cancer / HPV Vaccine | No Comments »
Thursday, May 15th, 2008
Although CDC recommends that girls receive the human papillomavirus vaccine at age 11 or 12 to protect against cervical cancer before the onset of sexual activity, mothers of girls under age 13 are less willing to have their daughters vaccinated than mothers of older girls, a new study has found, ...
Posted in Cervical Cancer / HPV Vaccine | No Comments »
Thursday, May 15th, 2008
Cervical cancer prevention relies on two different age-specific technologies, and consumers should not be misled about the role of human papillomavirus (HPV) vaccines, according to an article in the latest edition of The Medical Journal of Australia.Dr Gerard Wain, from the Department of Gynaecological Oncology at the Westmead Hospital in ...
Posted in Cervical Cancer / HPV Vaccine | No Comments »
Tuesday, April 8th, 2008
Educating preteens and teenagers about their sexual health is no easy task, even for many health care professionals. The Association of Women' s Health, Obstetric and Neonatal Nurses (AWHONN) hopes to change that, at least when it comes to talking about the human papillomavirus (HPV), with its newly released resource, ...
Posted in Cervical Cancer / HPV Vaccine | No Comments »
Tuesday, April 1st, 2008
1. Perils of Testing: What Happens When Tests for Cervical Cancer are Normal but HPV Testing Is Abnormal?When nearly 10,000 women were screened with Pap tests for cervical cancer and with DNA tests for high-risk human papillomavirus (HPV), 23 percent were found to be infected with high-risk HPV regardless of ...
Posted in Cervical Cancer / HPV Vaccine | No Comments »
Tuesday, April 1st, 2008
Gen-Probe Incorporated (Nasdaq: GPRO) announced that the Company has begun a pivotal U.S. clinical trial of its investigational APTIMA(R) assay to detect human papillomavirus (HPV), which causes cervical cancer. "Starting this highly complex, multi-center study was an important goal for Gen-Probe in early 2008," said ...
Posted in Cervical Cancer / HPV Vaccine | No Comments »
Saturday, March 29th, 2008
A recent CDC study that found that about 25% of female teenagers ages 14 to 19 have at least one common sexually transmitted infection should "reinvigorate" the debate over requiring human papillomavirus vaccines for school admission, a Washington Post editorial says. Although more than 20 states and Washington, D.C., recently ...
Posted in Cervical Cancer / HPV Vaccine | No Comments »
Friday, March 28th, 2008
A recent CDC study that found that about 25% of female teenagers ages 14 to 19 have at least one common sexually transmitted infection should "reinvigorate" the debate over requiring human papillomavirus vaccines for school admission, a Washington Post editorial says. Although more than 20 states and Washington, D.C., recently ...
Posted in Cervical Cancer / HPV Vaccine | No Comments »
Friday, March 28th, 2008
Nventa Biopharmaceuticals Corporation (TSX: NVN) announced interim immunological data from the first two cohorts of its ongoing Phase 1 clinical trial of its lead product candidate, HspE7, in patients with cervical intraepithelial neoplasia, or CIN, a precursor to cervical cancer. Preliminary evaluation of biological samples collected from the study's ...
Posted in Cervical Cancer / HPV Vaccine | No Comments »
Friday, March 28th, 2008
FDA has granted priority review status to Merck's application to expand marketing of its human papillomavirus vaccine Gardasil to women ages 27 to 45, the company said Wednesday, Reuters reports. The designation means that an FDA decision could come within six months, according to Reuters. currently is approved by the ...
Posted in Cervical Cancer / HPV Vaccine | No Comments »
Friday, March 28th, 2008
Merck & Co., Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted, and designated for priority review, the supplemental Biologics License Application (sBLA) for GARDASIL® [Human Papillomavirus Quadrivalent] (Types 6, 11, 16, 18) Vaccine, Recombinant] for the potential use in women aged 27 through 45. A ...
Posted in Cervical Cancer / HPV Vaccine | No Comments »
Friday, March 28th, 2008
The virus responsible for most cases of cervical cancer has a serious weakness which may provide hope for new treatments for the disease.Human Papillomavirus (HPV), a virus which causes several types of cancer but is particularly associated with cervical cancer, has developed clever ways of hiding in the body, but ...
Posted in Cervical Cancer / HPV Vaccine | No Comments »
Wednesday, March 26th, 2008
In a new collaborative study, the BC Cancer Agency, an agency of the Provincial Health Services Authority (PHSA), is trying to determine if a test for Human Papilloma Virus (HPV) can replace the standard Pap test as the primary method of cervical cancer screening, allowing women to be screened more ...
Posted in Cervical Cancer / HPV Vaccine | No Comments »
Monday, March 24th, 2008
FDA has granted priority review status to Merck's application to expand marketing of its human papillomavirus vaccine Gardasil to women ages 27 to 45, the company said Wednesday, Reuters reports. The designation means that an FDA decision could come within six months, according to Reuters. currently is approved by the ...
Posted in Cervical Cancer / HPV Vaccine | No Comments »